Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Qiu-Yue Li, John van den Anker, Yue-E Wu, Guo-Xiang Hao & Wei Zhao. (2023) Optimizing ganciclovir and valganciclovir dosing regimens in pediatric patients with cytomegalovirus infection: a spotlight on therapeutic drug monitoring. Expert Review of Clinical Pharmacology 16:8, pages 727-739.
Read now
Read now
Su Ann Ho, Monica Slavin, Jason A. Roberts & Michelle Yong. (2021) Optimization of Ganciclovir use in allogeneic hematopoietic cell transplant recipients – the role of therapeutic drug monitoring. Expert Review of Anti-infective Therapy 19:6, pages 707-718.
Read now
Read now
Elena Yu Enioutina, Jonathan E Constance, Chris Stockmann, Matthew W Linakis, Tian Yu, Joseph E Rower, Alfred H Balch & Catherine M Sherwin. (2015) Pharmacokinetic considerations in the use of antivirals in neonates. Expert Opinion on Drug Metabolism & Toxicology 11:12, pages 1861-1878.
Read now
Read now
Articles from other publishers (27)
Diana D. Wong, Su Ann Ho, Ana Domazetovska, Michelle K. Yong & William D. Rawlinson. (2023) Evidence supporting the use of therapeutic drug monitoring of ganciclovir in transplantation. Current Opinion in Infectious Diseases 36:6, pages 505-513.
Crossref
Crossref
Milo Gatti, Matteo Rinaldi, Luciano Potena, Elena Salvaterra, Maria Cristina Morelli, Maddalena Giannella, Pierluigi Viale & Federico Pea. (2023) Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non‐renal solid organ transplant recipients?. Transplant Infectious Disease 25:5.
Crossref
Crossref
Lena C. van der Wekken-Pas, Joan TottéFrans V. LunelArjan van Zuilen & Matthijs van Luin. (2023) Therapeutic Drug Monitoring of Ganciclovir in Cytomegalovirus-Infected Patients With Solid Organ Transplants and Its Correlation to Efficacy and Toxicity. Therapeutic Drug Monitoring 45:4, pages 533-538.
Crossref
Crossref
D. E. Dulek & M. I. Ardura. (2023) “Weight‐ing” for an answer on optimal valganciclovir prophylaxis dosing in pediatric solid organ transplantation recipients. Pediatric Transplantation 27:4.
Crossref
Crossref
Jocelyn Hume, Emma L. Sweeney, Kym Lowry, Chris Fraser, Julia E. Clark, David M. Whiley & Adam D. Irwin. (2023) Cytomegalovirus in children undergoing haematopoietic stem cell transplantation: a diagnostic and therapeutic approach to antiviral resistance. Frontiers in Pediatrics 11.
Crossref
Crossref
A. Facchin, N. Benyoub, V. Elie, S. Magreault & E. Jacqz-Aigrain. (2023) Limited Sampling Strategies to Predict Ganciclovir Exposure after Valganciclovir Administration and to Reduce Monitoring Constraints in Renal Transplant Children. Antimicrobial Agents and Chemotherapy 67:4.
Crossref
Crossref
Sjanene Marfil, Anne-Grete Märtson, Marlous Toren-Wielema, Coretta Leer-Buter, Elisabeth H. Schölvinck, Jan-Willem C. Alffenaar, Daan J. Touw & Marieke G. G. Sturkenboom. (2023) Subtherapeutic Exposure of Ganciclovir in Children Despite Appropriate Dosing: A Short Communication. Therapeutic Drug Monitoring 45:2, pages 269-272.
Crossref
Crossref
Elaine E. To. (2023) Cell and Tissue Specific Metabolism of Nucleoside and Nucleotide Drugs: Case Studies and Implications for Precision Medicine. Drug Metabolism and Disposition 51:3, pages 360-368.
Crossref
Crossref
Bénédicte Franck, Julie Autmizguine, Pierre Marquet, Philippe Ovetchkine & Jean‐Baptiste Woillard. (2021) Pharmacokinetics, Pharmacodynamics, and Therapeutic Drug Monitoring of Valganciclovir and Ganciclovir in Transplantation. Clinical Pharmacology & Therapeutics 112:2, pages 233-276.
Crossref
Crossref
Eliška Dvořáčková, Martin Šíma, Jakub Petrus, Eva Klapková, Petr Hubáček, Jiří Pozniak, Jan Havlín, Robert Lischke & Ondřej Slanař. (2022) Ganciclovir Pharmacokinetics and Individualized Dosing Based on Covariate in Lung Transplant Recipients. Pharmaceutics 14:2, pages 408.
Crossref
Crossref
Anne-Grete Märtson, Marieke G. G. Sturkenboom, Marjolein Knoester, Tjip S. van der Werf, Jan-Willem C. Alffenaar, William Hope, Angela E. Edwina, Johannes G. M. Burgerhof, Stefan P. Berger, Anoek de Joode, Kevin Damman, Erik A. M. Verschuuren, Hans Blokzijl, Martijn Bakker, Daan J. Touw, Anne-Grete Mä rtson, Marieke G. G. Sturkenboom, Marjolein Knoester, Tjip S. van der Werf & Jan-Willem C. Alffenaar. (2022) Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads. Journal of Antimicrobial Chemotherapy 77:2, pages 466-473.
Crossref
Crossref
Anne-Grete Märtson, Angela E. Edwina, Hannah Yejin Kim, Marjolein Knoester, Daan J. Touw, Marieke G. G. Sturkenboom & Jan-Willem C. Alffenaar. (2022) Therapeutic Drug Monitoring of Ganciclovir: Where Are We?. Therapeutic Drug Monitoring 44:1, pages 138-147.
Crossref
Crossref
Shanmugam Hemaiswarya, Pranav Kumar Prabhakar & Mukesh DobleShanmugam Hemaiswarya, Pranav Kumar Prabhakar & Mukesh Doble. 2022. Herb-Drug Combinations. Herb-Drug Combinations
103
130
.
Xavier Duval, Florian Lemaitre, Sophie Pertuisel, Jamie Probert, Virginie Gandemer, Marie-Clémence Verdier & Camille Tron. (2021) The need for area under the curve measurements in the field of ganciclovir therapeutic drug monitoring in children: a case report. BMC Infectious Diseases 21:1.
Crossref
Crossref
Bénédicte Franck, Julie Autmizguine, Anders Åsberg, Yves Théorêt, Pierre Marquet, Philippe Ovetchkine & Jean-Baptiste Woillard. (2021) Thoroughly Validated Bayesian Estimator and Limited Sampling Strategy for Dose Individualization of Ganciclovir and Valganciclovir in Pediatric Transplant Recipients. Clinical Pharmacokinetics 60:11, pages 1449-1462.
Crossref
Crossref
Anne-Grete Märtson, Angela E. Edwina, Johannes G. M. Burgerhof, Stefan P. Berger, Anoek de Joode, Kevin Damman, Erik A. M. Verschuuren, Hans Blokzijl, Martijn Bakker, Lambert F. Span, Tjip S. van der Werf, Daan J. Touw, Marieke G. G. Sturkenboom, Marjolein Knoester & Jan W. C. Alffenaar. (2021) Ganciclovir therapeutic drug monitoring in transplant recipients. Journal of Antimicrobial Chemotherapy 76:9, pages 2356-2363.
Crossref
Crossref
Bénédicte Franck, Jean‐Baptiste Woillard, Yves Théorêt, Henrique Bittencourt, Emile Demers, Annabelle Briand, Pierre Marquet, Anne‐Laure Lapeyraque, Philippe Ovetchkine & Julie Autmizguine. (2021) Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients. British Journal of Clinical Pharmacology 87:8, pages 3105-3114.
Crossref
Crossref
Bing Chen, Shan‐Shan Hu, Wen‐Bin Rui, Hui‐Min An, Xiao‐Hui Zhai, Xi‐Han Wang, Jia‐Qian Lu, Kun Shao & Pei‐Jun Zhou. (2020) Population Pharmacokinetics and Bayesian Estimation of the Area Under the Concentration‐Time Curve for Ganciclovir in Adult Chinese Renal Allograft Recipients After Valganciclovir Administration. The Journal of Clinical Pharmacology 61:3, pages 328-338.
Crossref
Crossref
T. Nguyen, M. Oualha, C. Briand, M. Bendavid, A. Béranger, S. Benaboud, J.-M. Tréluyer, Y. Zheng, F. Foissac, S. Winter, I. Gana, S. Boujaafar, V. Lopez, R. Berthaud, Z. Demir, N. Bouazza & D. Hirt. (2021) Population Pharmacokinetics of Intravenous Ganciclovir and Oral Valganciclovir in a Pediatric Population To Optimize Dosing Regimens. Antimicrobial Agents and Chemotherapy 65:3.
Crossref
Crossref
SiChan Li, Chang Shu, SanLan Wu, Hua Xu & Yang Wang. (2021) Population Pharmacokinetics and Dose Optimization of Ganciclovir in Critically Ill Children. Frontiers in Pharmacology 11.
Crossref
Crossref
A. Facchin, V. Elie, N. Benyoub, S. Magreault, A. Maisin, T. Storme, W. Zhao, G. Deschenes & E. Jacqz-Aigrain. (2019) Population Pharmacokinetics of Ganciclovir after Valganciclovir Treatment in Children with Renal Transplant. Antimicrobial Agents and Chemotherapy 63:12.
Crossref
Crossref
Yi Guo & Li Jiang. (2019) Cytomegalovirus encephalitis in immunocompetent infants: A 15-year retrospective study at a single center. International Journal of Infectious Diseases 82, pages 106-110.
Crossref
Crossref
Karin Jorga, Bruno Reigner, Clarisse Chavanne, Giuseppe Alvaro & Nicolas Frey. (2018) Pediatric Dosing of Ganciclovir and Valganciclovir: How Model‐Based Simulations Can Prevent Underexposure and Potential Treatment Failure. CPT: Pharmacometrics & Systems Pharmacology 8:3, pages 167-176.
Crossref
Crossref
Qian Dong, Stephanie Leroux, Hai-Yan Shi, Hai-Yan Xu, Chen Kou, Muhammad Wasim Khan, Evelyne Jacqz-Aigrain & Wei Zhao. (2018) Pilot Study of Model-Based Dosage Individualization of Ganciclovir in Neonates and Young Infants with Congenital Cytomegalovirus Infection. Antimicrobial Agents and Chemotherapy 62:5.
Crossref
Crossref
Abdullah A. Al-Badr & Tariq D.S. Ajarim. 2018.
1
208
.
Orit PeledMatitiahu BerkovitchEran RomEfraim BilavskyYael BernfeldLev DorfmanAdi PappoTomer Ziv-BaranNurit BrandrissAdina Bar-HaimJacob AmirLiat Ashkenazi-Hoffnung. (2017) Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients. Pediatric Infectious Disease Journal 36:8, pages 745-750.
Crossref
Crossref
Thomas Skripuletz, Laura Salinas Tejedor, Chittappen K. Prajeeth, Florian Hansmann, Chintan Chhatbar, Valeria Kucman, Ning Zhang, Barbara B. Raddatz, Claudia N. Detje, Kurt-Wolfram Sühs, Refik Pul, Viktoria Gudi, Ulrich Kalinke, Wolfgang Baumgärtner & Martin Stangel. (2015) The antiviral drug ganciclovir does not inhibit microglial proliferation and activation. Scientific Reports 5:1.
Crossref
Crossref